Home
Halfdan Sørbye's picture

Halfdan Sørbye

Professor
  • E-mailHalfdan.Sorbye@uib.no
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) 2021. Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms. Journal of neuroendocrinology. 1-12.
  • Show author(s) 2021. Quality of life in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy—the randomized nordic9-study. Cancers. 1-17.
  • Show author(s) 2020. Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors. Neuroendocrinology. 217-224.
  • Show author(s) 2020. Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours. Health and Quality of Life Outcomes. 1-11.
  • Show author(s) 2020. PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3. PLOS ONE. 1-12.
  • Show author(s) 2020. Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis. Acta Oncologica. 417-426.
  • Show author(s) 2020. Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3. Scientific Reports. 1-9.
  • Show author(s) 2020. CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup . Frontiers in Oncology. 1-11.
  • Show author(s) 2020. A plasma protein biomarker strategy for detection of small intestinal neuroendocrine tumors. Neuroendocrinology.
  • Show author(s) 2020. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations. Neuroendocrinology. 1-12.
  • Show author(s) 2019. Unmet needs in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Neuroendocrinology. 54-62.
  • Show author(s) 2019. Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy. Annals of Oncology. 1088-1095.
  • Show author(s) 2019. Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach. European Journal of Health Economics. 1-14.
  • Show author(s) 2019. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. The Lancet Gastroenterology and Hepatology. 376-388.
  • Show author(s) 2019. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: A multicenter cohort study. Endocrine-Related Cancer. 227-239.
  • Show author(s) 2019. Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study. Acta Oncologica. 1-8.
  • Show author(s) 2019. Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients. Cancer Medicine. 3623-3635.
  • Show author(s) 2018. The problem of high-grade gastroenteropancreatic neuroendocrine neoplasms: Well-differentiated neuroendocrine tumors, neuroendocrine carcinomas, and beyond. Endocrinology and metabolism clinics of North America (Print). 683-698.
  • Show author(s) 2018. Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. British Journal of Cancer. 1609-1616.
  • Show author(s) 2018. Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Medical Oncology (MO).
  • Show author(s) 2018. Cost-effectiveness of liver transplantation in patients with colorectal metastases confined to the liver. British Journal of Surgery.
  • Show author(s) 2018. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. European Journal of Cancer. 35-45.
  • Show author(s) 2018. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer. 807-815.
  • Show author(s) 2017. Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer. Virchows Archiv. 1-11.
  • Show author(s) 2017. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. European Journal of Surgical Oncology. 1682-1689.
  • Show author(s) 2017. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. BMC Cancer.
  • Show author(s) 2017. Population-based study on resection rates and survival in patients with colorectal liver metastasis in Norway. British Journal of Surgery. 580-589.
  • Show author(s) 2017. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial. BMC Surgery.
  • Show author(s) 2017. High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. PLOS ONE. 1-13.
  • Show author(s) 2017. Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status. European Journal of Cancer. 26-35.
  • Show author(s) 2017. Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. PLOS ONE. 1-15.
  • Show author(s) 2017. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology-Diagnosis and Prognostic Stratification. Neuroendocrinology. 196-200.
  • Show author(s) 2017. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Chemotherapy. Neuroendocrinology. 281-294.
  • Show author(s) 2017. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Biotherapy and Novel Targeted Agents. Neuroendocrinology. 266-280.
  • Show author(s) 2017. Cetuximab in treatment of metastatic colorectal cancer: Final survival analyses and extended RAS data from the NORDIC-VII study. British Journal of Cancer. 1271-1278.
  • Show author(s) 2017. A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors. Endocrine-Related Cancer. 427-443.
  • Show author(s) 2016. TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer. OncoTarget. 59441-59457.
  • Show author(s) 2016. Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer. OncoTarget. 41948-41958.
  • Show author(s) 2016. Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study. Annals of Surgical Oncology. 1721-1728.
  • Show author(s) 2016. Intra-patient inter-metastatic genetic heterogeneity in colorectal cancer as a key determinant of survival after curative liver resection. PLoS Genetics. 22 pages.
  • Show author(s) 2016. Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. OncoTarget. 75013-75022.
  • Show author(s) 2016. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. International Journal of Cancer. 647-656.
  • Show author(s) 2016. Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review. Acta Oncologica. 881-885.
  • Show author(s) 2016. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 186-194.
  • Show author(s) 2016. Drug costs and benefits of medical treatments in high-unmet need solid tumours in the Nordic countries. Journal of Cancer Policy. 12-22.
  • Show author(s) 2016. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. Journal of Controlled Release. 172-181.
  • Show author(s) 2015. Review on adjuvant chemotherapy for rectal cancer-why do treatment guidelines differ so much? Acta Oncologica. 437-446.
  • Show author(s) 2015. Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. European Journal of Cancer. 2708-2717.
  • Show author(s) 2015. Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases. World Journal of Surgical Oncology (WJSO).
  • Show author(s) 2015. Modeling and Validating the Cost and Clinical Pathway of Colorectal Cancer. Medical decision making. 255-265.
  • Show author(s) 2015. Maintenance therapy with cetuximab every second week in the first-line treatment of metastatic colorectal cancer: the NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group. Clinical colorectal cancer. 170-176.
  • Show author(s) 2015. Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. International Journal of Cancer. 2470-2477.
  • Show author(s) 2015. High BRAF mutation frequency and marked survival differences in subgroups according to KRAS/BRAF mutation status and tumor tissue availability in a prospective population-based metastatic colorectal cancer cohort. PLOS ONE.
  • Show author(s) 2014. Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: Results from the NORDIC VII Study. PLOS ONE.
  • Show author(s) 2014. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncologica. 1284-1297.
  • Show author(s) 2014. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. European Journal of Cancer. 912-919.
  • Show author(s) 2013. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Annals of Oncology. 152-160.
  • Show author(s) 2013. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. The Lancet Oncology. 1208-1215.
  • Show author(s) 2013. Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer. Annals of Oncology. 2354-2360.
  • Show author(s) 2012. Small Cell Lung Cancer in a 14-Year-Old Girl. Journal of Pediatric Hematology/Oncology. E86-E88.
  • Show author(s) 2012. Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983). Annals of Surgery. 534-539.
  • Show author(s) 2012. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The NORDIC-VII Study. Journal of Clinical Oncology. 1755-1762.
  • Show author(s) 2012. Lower treatment intensity and poorer survival in metastatic colorectal cancer patients who live alone. British Journal of Cancer. 189-194.
  • Show author(s) 2012. Let-7 miRNA-binding site polymorphism in the KRAS 3 ' UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab. BMC Cancer.
  • Show author(s) 2012. Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study. British Journal of Cancer. 435-441.
  • Show author(s) 2012. Combination Chemotherapy in Advanced Adrenocortical Carcinoma. New England Journal of Medicine. 2189-2197.
  • Show author(s) 2011. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. The Pharmacogenomics Journal. 61-71.
  • Show author(s) 2011. Clinical effect of Temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. 4617-4622.
  • Show author(s) 2010. Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncologica. 740-756.
  • Show author(s) 2009. Clinical Trial Enrollment, Patient Characteristics, and Survival Differences in Prospectively Registered Metastatic Colorectal Cancer Patients. Cancer. 4679-4687.
  • Show author(s) 2008. Prognostic clinical factors in metastatic colorectal cancer. Advances in Gastrointestinal Cancers. 6-8.
  • Show author(s) 2008. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. The Lancet. 1007-1016.
  • Show author(s) 2008. Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil. Annals of Oncology. 1154-1159.
  • Show author(s) 2008. A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Annals of Oncology. 909-914.
  • Show author(s) 2005. SSucralfate does not ameliorate acute radiation proctitis: Randomised study and meta-analysis. Clinical Oncology. 485-491.
  • Show author(s) 2004. Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncologica. 495-498.
  • Show author(s) 2004. Multicentre phase II study of Nordic 5-fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. Journal of Clinical Oncology. 31-38.
  • Show author(s) 2003. Profiles and time course of acute radiation toxicity symptoms during conformal radiotherapy for cancer of the prostate. Acta Oncologica. 741-748.
  • Show author(s) 2003. Nordic 5-Fluorouracil/Leucovorin bolus schedule combined with Oxaliplatin (Nordic FLOX)as first-line treatment of metastatic colorectal cancer. Acta Oncologica. 827-831.
  • Show author(s) 2003. Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to Oxaliplatin combination chemotherapy: Implications for tumor marker monitoring and guidelines. Journal of Clinical Oncology. 4466-4467.
  • Show author(s) 2002. Ulceration as a possible link between duodenogastric reflux and neoplasms in the stomach of rats. Journal of Surgical Research. 167-178.
  • Show author(s) 2002. Gastric mucosa lesions induced by duodenogastric reflux increase the penetration of N-[3H]-methyl-N-nitro-N-nitrosoguanidine into the corpus mucosa of rats. Digestive Diseases and Sciences. 2354-2369.
  • Show author(s) 2002. Duodenogastric reflux increases the penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into the antral mucosa of rats. A possible role for mucosal erosions and increased cell proliferation in gastric carsinogenesis. Japanese Journal of Cancer Research. 484-494.
  • Show author(s) 2001. Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and hemolysis. Case report. Acta Oncologica. 882-883.
  • Show author(s) 1999. Glutathione modulation changes the penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into the gastric mucosa of rats. Digestive Diseases and Sciences. 2063-2075.
  • Show author(s) 1998. Lymphocele after retroperitoneal surgery for testicular or extragonadal germ cell tumors may mimic recurrence. Urology. 833-834.
  • Show author(s) 1998. Lymphocele after retroperitoneal surgery for testicular or extragonadal germ cell tumors may mimic recurrence. Urology. 833-834.
  • Show author(s) 1998. Effect of gastric secretion on the penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into the gastric mucosa of rats. Digestive Diseases and Sciences. 2012-2020.
  • Show author(s) 1997. Glutathione and N-acetylcysteine reduce gastric mucosal blood flow in rats. Digestive Diseases and Sciences. 1765-1774.
  • Show author(s) 1993. Gastric mucosal injury and associated changes in mucosal blood flow and gastric fluid secretion caused by dimethyl sulphoxide (DMSO) in rats. Digestive Diseases and Sciences. 1243-1250.
Report
  • Show author(s) 2007. Health economic evaluation of bevacizumab for metastatic colorectal cancer. 23/2007. 23/2007. .
Academic lecture
  • Show author(s) 2015. Modell for å beregne overlevelse og kostnader av behandling for kolorektal cancer.
  • Show author(s) 2005. A randomised phase III multicenter trial comparing irinotecan in combination with 5FU and folinic acid (FU/FA) given according to the Nordic bolus schedule to irinotecan in combination with 5FU/FA given according to the bolus/infused de Gramont schedule, in patients with metastatic colorectal cancer.
Editorial
  • Show author(s) 2012. Palliative chemotherapy in elderly patients with metastatic colorectal cancer: Do we know how it should be used? Acta Oncologica. 819-821.
Reader opinion piece
  • Show author(s) 2019. Ekspertpanel for ny vurdering ved alvorlig sykdom. Tidsskrift for Den norske legeforening. 2 pages.
Short communication
  • Show author(s) 2008. Surgery vs surgery and chemotherapy for colorectal liver metastases. The Lancet. 203.
Doctoral dissertation
  • Show author(s) 1994. Penetration of carcinogens into normal and damaged gastric mucosa.
Academic chapter/article/Conference paper
  • Show author(s) 2014. Recurrence Patterns After Resection of Liver Metastases from Colorectal Cancer. 10 pages.
  • Show author(s) 2013. Ultrasound-assisted treatment of an inoperable pancreatic cancer. 4 pages.
  • Show author(s) 2009. Endokrine svulster. 9 pages.
  • Show author(s) 2008. The use of Chemotherapy for Neuroendocrine Tumors. 6 pages.
  • Show author(s) 1999. Antimetabolitter. 20 pages.
Abstract
  • Show author(s) 2019. Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results. Annals of Oncology. iv131-iv131.
  • Show author(s) 2018. Total circulating cell-free DNA (cfDNA) as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy. Annals of Oncology. v109-v109.
  • Show author(s) 2016. Ultrasound and microbubble enhanced treatment of inoperable pancreatic adeonocarcinoma. Journal of Clinical Oncology.
  • Show author(s) 2013. Ki-67 Proliferative Index Predicts Response to Chemotherapy and Survival in 252 Patients with High-Grade Gastrointestinal Neuroendocrine Carcinoma (WHO G3). Pancreas. 382-382.
  • Show author(s) 2012. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal poorly differentiated neuroendocrine carcinoma: The NORDIC NEC study. Journal of Clinical Oncology. 1 pages.
  • Show author(s) 2012. Plasma concentrations of YKL-40 in chemo-naive patients with metastatic colorectal cancer treated with FLOX with or without cetuximab: Results from the NORDIC VII study. Journal of Clinical Oncology. 1 pages.
  • Show author(s) 2012. Maintenance therapy with biweekly cetuximab (C) in the first-line treatment of metastatic colorectal cancer (mCRC): The NORDIC 7.5 study (NCT00660582), by the Nordic Colorectal Cancer Biomodulation Group. Journal of Clinical Oncology. 1 pages.
  • Show author(s) 2012. Long term survival data from EORTC Study 40983:perioperative chemotherapy for resectable liver metastasesfrom colorectal cancer. Annals of Oncology. 18-18.
  • Show author(s) 2012. EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results. Journal of Clinical Oncology. 1 pages.
  • Show author(s) 2012. AGE DEPENDENT INCREASE IN MEDIAN AND LONG-TERM SURVIVAL IN 29 628 METASTATIC COLORECTAL CANCER (MCRC) SCANDINAVIAN PATIENTS DURING THE PAST TWO DECADES. Annals of Oncology. 188-188.
  • Show author(s) 2010. Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: the Nordic VII study (NCT00145314), by the Nordic colorectal cancer biomodulation group. Annals of Oncology. 9-9.
  • Show author(s) 2006. Tumor response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM). Interim results of EORTC Intergroup randomized phase III study 40983. Journal of Clinical Oncology. 146S-146S.
  • Show author(s) 2005. Feasibility and risks of pre-operative chemotherapy (CT) with Folfox 4 and surgery for resectable colorectal cancer liver metastases (LM). Interim results of the EORTC Intergroup randomized phase III study 40983. Journal of Clinical Oncology. 253S-253S.
Poster
  • Show author(s) 2014. Development and validation of a Norwegian model for colorectal cancer.
  • Show author(s) 2003. Nordic 5-fluorouracil/folinic acid bolus schedule combined with oxaliplatin (FLOX) as first-line treatment to metastatic colorectal cancer.
Errata
  • Show author(s) 2016. Erratum: Corrigendum to "2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer" (European Journal of Cancer (2016) 68 (208?209) (S0959804916320780) (10.1016/j.ejca.2016.04.010)). European Journal of Cancer. 208-209.
Academic literature review
  • Show author(s) 2020. PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Endocrine-Related Cancer. R67-R77.
  • Show author(s) 2018. Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. European Journal of Cancer. 115-124.
  • Show author(s) 2016. Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer. European Journal of Cancer. 11-24.
  • Show author(s) 2014. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2814-2823.
  • Show author(s) 2009. Positronemisjonstomografi ved nevroendokrine svulster. Tidsskrift for Den norske legeforening. 1474-1477.
  • Show author(s) 2008. Palliativ kjemoterapi og strålebehandling ved metastatisk kolorectalkreft. Tidsskrift for Den norske legeforening. 194-197.

More information in national current research information system (CRIStin)